[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-aging":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100639636","the-bone-and-heart-health-consequences-of-ovarian-aging-beacon-study-100639636",false,"NCT07621965","The Bone and hEArt Health Consequences of Ovarian agiNg (BEACON) Study","BEACON","Inclusion Criteria:\n\n* We will include all IU study participants (n=655) for these analyses to characterize the ovarian aging trajectory of the cohort over time. The approach will allow us to move forward with the ovarian aging biomarker assays while recruitment for the in-person visit is ongoing. We will recruit a subgroup of current the IU cohort (n=352) to complete an in-person study visit at the FIT Core and Clinical Research Center. We will only recruit those who are at least 35 years old to this subgroup.\n\nExclusion Criteria:\n\n* We will exclude any potential participants who are unable to provide written informed consent in English or Spanish (the only languages allowed at the IU site for nuMoM2b), if the participant is currently pregnant, has undergone recent major surgery or sustained major injury or broken bones within 6 months of recruitment.","FEMALE",{"count":18,"type":19},655,"ESTIMATED","OBSERVATIONAL","Ovarian aging is a major driver of a woman's long-term health and disease risk. In particular, the rapid decline in the ovarian reserve that occurs with the menopause transition is linked to a striking increase in the risk for both cardiometabolic disease and osteoporosis. A growing body of evidence has demonstrated that earlier age at menopause further exacerbates this risk for ischemic stroke, heart disease, and non-traumatic osteoporotic fracture. Thus, the identification of factors that accelerate ovarian aging is likely to lead to increased incidence and earlier onset of these conditions. Adverse pregnancy outcomes (APO) such as gestational diabetes, hypertensive disorders of pregnancy, and stillbirth, are major pathophysiological states that have the potential to accelerate depletion of the ovarian reserve due to the chronic inflammatory state, oxidative stress, and epigenetics changes that ensue. This proposal seeks to determine if APOs impact the ovarian aging trajectory and subsequent cardiometabolic and musculoskeletal health outcomes. Our central hypothesis is that APOs will accelerate ovarian aging, resulting in greater incidence and earlier onset of cardiometabolic disease and musculoskeletal decline. This hypothesis will be tested by accomplishing three aims designed to: 1) define the trajectory of ovarian aging and the impact of APOs on indicators of ovarian aging over time; 2) correlate the ovarian aging trajectory with the development of cardiometabolic risk; and 3) determine the association of ovarian aging biomarker trajectory on musculoskeletal health. To accomplish these aims we will capitalize on a subset of participants from the large, multisite nuMoM2b cohort that has been followed for fifteen years since the time of their first pregnancy. This project, the Bone and hEArt health Consequences of Ovarian agiNg (BEACON) Study, will utilize the extensive health, behavior, psychosocial and pregnancy data in this cohort, paired with biospecimens from their initial pregnancy and follow-up visits (3-7 \\& 7-12 years after pregnancy), as well as data and specimens collected on participants completing an additional study visit. This proposal has the unique opportunity to provide longitudinal insight into the role of APOs in ovarian aging. If APOs are shown to accelerate ovarian aging, this mechanism may contribute to earlier onset of vascular dysfunction, metabolic disease, and musculoskeletal decline that would highlight the need for revised risk stratification for women with APOs, earlier screening (e.g., bone density, blood pressure \\& lipids), and the development of targeted prevention strategies. Moreover, these findings could identify critical windows for intervention and reveal novel targets for earlier and more effective therapeutic strategies.",[23,24],"Ovarian Aging","Adverse Pregnancy Outcomes",[26,27,28,29,30],"ovarian aging","perimenopause","menopause","cardiovascular health","musculoskeletal health","NOT_YET_RECRUITING","2026-05-27",{"date":34,"type":35},"2026-06-02","ACTUAL",{"date":37,"type":19},"2027-04-01",{"date":39,"type":19},"2032-03-30",{"name":41,"class":42},"Indiana University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100579955","the-roar-study-reactive-oxygen-species-and-reproduction-100579955","NCT06831019","The ROAR Study: Reactive Oxygen Species and Reproduction","ROAR","Inclusion Criteria:\n\n1. Female age 18-43 years\n2. Subjects planning blastocyst culture for preimplantation genetic screening (PGS) for aneuploidy.\n3. Male partners 18 years of age or older.\n4. Must be a registered patient at UCSF Center for Reproductive Health\n5. Patient and partner must both be physically present on the day of retreival\n\nExclusion Criteria:\n\n1. Female partner age 44 or older\n2. Planning fresh transfer (hybrid PGS cycle)\n3. Cleavage stage biopsy\n4. Planning to use frozen sperm",true,"ALL","18 Years","43 Years",{"count":55,"type":19},1100,"This is a prospective cohort study characterizing follicular fluid and serum levels of oxidative stress in women with various infertility diagnoses undergoing in vitro fertilization, and assessing the relationship of oxidative stress to oocyte competence as determined by embryo development outcomes. Furthermore, we will measure oxidative stress in sperm and correlate the overall oxidative stress within the couple with IVF and pregnancy outcomes of the resultant embryos.",[23,58,59],"IVF Outcome","Oxidative Stress",[61,26],"oxidative stress","RECRUITING","2026-02-12",{"date":65,"type":35},"2026-02-17",{"date":67,"type":35},"2025-07-07",{"date":69,"type":19},"2027-03-01",{"name":71,"class":42},"University of California, San Francisco",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":72},"100609412","follicular-fluid-micrornas-in-ovarian-aging-and-reproduction-100609412","NCT07214246","Follicular Fluid microRNAs in Ovarian Aging and Reproduction","Investigating the Role of Follicular Fluid microRNAs in Ovarian Aging and Assisted Reproductive Success","Inclusion Criteria:\n\n* Women undergoing IVF treatment due to male factor infertility or nonovarian causes.\n* Age groups: younger women \\\u003C31 years and older women \\>38 years.\n* Regular menstrual cycles.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Minors (under 18 years) and women aged 32-37 years\n* Diagnosis of polycystic ovarian syndrome (PCOS).\n* History of recurrent pregnancy loss.\n* Presence of endometriosis.\n* Diagnosis of ovarian insufficiency.\n* Metabolic disorders (e.g., diabetes).\n* History of ovarian surgery or chemotherapy.\n* Any condition that might impact follicular fluid quality or IVF outcomes.",{"count":81,"type":19},100,"The purpose of this study is to investigate the role of exosomal microRNAs (miRNAs) in follicular fluid (FF) as biomarkers of ovarian aging and predictors of in vitro fertilization (IVF) outcomes. The goal is to identify noninvasive molecular markers that correlate with oocyte quality and reproductive potential, particularly in women of advanced maternal age.",[23,84,85,86],"In Vitro Fertilisation (IVF) Treatment","InVitro Fertilization","In Vitro Fertilization Outcome",[88,89,90],"IVF","In vitro fertilization","Follicular fluid","2025-10-08",{"date":93,"type":35},"2025-10-09",{"date":95,"type":35},"2025-09-22",{"date":97,"type":19},"2026-09",{"name":99,"class":42},"University of Central Florida"]